Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) FCF Margin: 2013-2025

Historic FCF Margin for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to -32.56%.

  • Theravance Biopharma's FCF Margin fell 166.00% to -32.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 303.15%, marking a year-over-year increase of 32263.00%. This contributed to the annual value of -18.43% for FY2024, which is 3291.00% up from last year.
  • Per Theravance Biopharma's latest filing, its FCF Margin stood at -32.56% for Q3 2025, which was down 104.10% from 794.33% recorded in Q2 2025.
  • Theravance Biopharma's FCF Margin's 5-year high stood at 794.33% during Q2 2025, with a 5-year trough of -1,077.36% in Q1 2022.
  • Its 3-year average for FCF Margin is 66.16%, with a median of -15.98% in 2023.
  • Per our database at Business Quant, Theravance Biopharma's FCF Margin surged by 323,457bps in 2021 and then slumped by 57,493bps in 2022.
  • Theravance Biopharma's FCF Margin (Quarterly) stood at -305.73% in 2021, then tumbled by 54,294bps to -848.67% in 2022, then spiked by 83,995bps to -8.72% in 2023, then soared by 289bps to -5.82% in 2024, then tumbled by 166bps to -32.56% in 2025.
  • Its last three reported values are -32.56% in Q3 2025, 794.33% for Q2 2025, and 279.69% during Q1 2025.